Title:Organotin(IV) Carboxylates as Promising Potential Drug Candidates in the Field of Cancer Chemotherapy
Volume: 22
Issue: 44
Author(s): Muhammad Sirajuddin and Saqib Ali
Affiliation:
Keywords:
Cancer Chemotherapy, cis-platin, metal–based compounds, chemotherapeutic agents.
Abstract: Medicinal inorganic chemistry plays an important role in exploring the properties
of metal ions for the designing of new drugs. The field has been stimulated by the success of
cis-platin, the world best selling anticancer drug and platinum complexes with reduced toxicity,
oral activity and activity against resistant tumors are currently on clinical trial. The use of
cis-platin is, however, severely limited by its toxic side-effects. This has stimulated chemists
to employ different strategies in the development of new metal-based anticancer agents with
different mechanisms of action. The discovery of new non-covalent interactions with the
classical target, DNA, was the first developing step in the treatment of cancer. The use of
organometallic compounds as a medicine is very common now a days because it offers potential
advantages over the more common organic-based drugs. In this article we have highlighted
the anticancer activity of the organotin(IV) carboxylates published in the last few
years (from 2008 to 2016). In most cases they present lower IC50 values than those of cisplatin,
which indicates their high activity against the cancer cell lines. The summarized data reveal that every year
new organotin(IV) carboxylate complexes are synthesized with the aim of new anticancer agent with much better
results than the than the corresponding activity of cis-platin or other clinically approved drugs. In addition to the
advantages of high activity, compared to the platinum compound, tin complexes are much cheaper. Thus by using
organotin carboxylate for clinical medicine, cost reduction, dosage reduction and effect enhancement will be
reached.
